First Opinion

First Opinion

Lost lives and long odds: Inside STAT’s decision to take on Purdue

By Gideon Gil

First Opinion

Stop treating medical residents like indentured servants

By Kim-Lien Nguyen

First Opinion

Community engagement is key to clinical trial recruitment and diversity

By Bobby Clark and Ronnie Tepp

First Opinion

Gene editing to stop Lyme disease: caution is warranted

By Allison Snow

First Opinion

A community-guided genome editing project can fight Lyme disease

By Kevin M. Esvelt

First Opinion

Trump is trying to end secret health care price negotiations. You should be on his side

By David Vivero

First Opinion

FDA should use its existing program to qualify new tools for drug safety testing

By Elizabeth Baker

First Opinion

Containing the Ebola outbreak means addressing its root causes: a weak health system and insecurity

By Joel G. Breman

First Opinion

Virtual and augmented reality can save lives by improving surgeons’ training

By Justin Barad

First Opinion

Cannabidiol confusion: lofty promises and barriers to research

By Beatriz H. Carlini, Gregory Carter, and Nephi Stella

First Opinion

With no dementia cure in sight, it’s time for communities to become dementia friendly

By Nancy Berlinger

First Opinion

Novartis violated FDA’s sacred principle: In God we trust, all others must bring data

By Robert M. Califf

transparency in healthcare - executive order

First Opinion

Bringing transparency to the notion of price transparency

By Robin Gelburd

First Opinion

Five things I wish I knew earlier in my journey with chronic pain

By Tom Bowen

First Opinion

Medicare’s ‘new technology’ payment plan doesn’t go far enough

By Roy Silverstein

First Opinion

Presidential candidates aren’t talking about drug shortages. They should be

By David Introcaso and Zack Szlezinger

First Opinion

23andMe had devastating news about my health. I wish a person had delivered it

By Dorothy Pomerantz

First Opinion

Scribes can help transform health care by creating better clinical data

By Robert Merold

First Opinion

Toy magnets are harming kids again. They need to be banned — for good

By Amy Garcia and Sanjay Krishnaswami

First Opinion

Some people should stop being screened for cancer. Convincing them isn’t always easy

By Nancy L. Schoenborn

Opinions Plus

How to create successful leadership teams for cell and gene therapy companies

By Nick Stephens

First Opinion

Rural Americans need help with ‘deaths of despair.’ Repealing the ACA won’t do that

By Nickolas D. Zaller

First Opinion

Why the term ‘natural’ is so seductive — and possibly misleading

By Brian Meier, Amanda Dillard, and Courtney Lappas

First Opinion

How our health systems are working to prevent hospital drug shortages

By Barclay E. Berdan, Scott Reiner, and Terry Shaw

First Opinion

Why health companies are branding themselves as tech companies

By Samyukta Mullangi and Medha Vyavahare

Are reasonable restraints on drug price increases doomed by pharma lobbying?

My hand surgeon should have been paid $4.5 billion for fixing my broken wrist, not $1,000

Artificial intelligence for medicine needs a Turing test. Obesity would be a good one

Transplanting islet cells can fix brittle diabetes. Why isn’t it available in the U.S.?

Lost lives and long odds: Inside STAT’s decision to take on Purdue

Stop treating medical residents like indentured servants

Community engagement is key to clinical trial recruitment and diversity

Gene editing to stop Lyme disease: caution is warranted

A community-guided genome editing project can fight Lyme disease

Trump is trying to end secret health care price negotiations. You should be on his side

FDA should use its existing program to qualify new tools for drug safety testing

Containing the Ebola outbreak means addressing its root causes: a weak health system and insecurity

Virtual and augmented reality can save lives by improving surgeons’ training

Cannabidiol confusion: lofty promises and barriers to research

With no dementia cure in sight, it’s time for communities to become dementia friendly

Novartis violated FDA’s sacred principle: In God we trust, all others must bring data

Bringing transparency to the notion of price transparency

Five things I wish I knew earlier in my journey with chronic pain

Medicare’s ‘new technology’ payment plan doesn’t go far enough

Presidential candidates aren’t talking about drug shortages. They should be

23andMe had devastating news about my health. I wish a person had delivered it

Scribes can help transform health care by creating better clinical data

Toy magnets are harming kids again. They need to be banned — for good

Some people should stop being screened for cancer. Convincing them isn’t always easy

How to create successful leadership teams for cell and gene therapy companies

Rural Americans need help with ‘deaths of despair.’ Repealing the ACA won’t do that

Why the term ‘natural’ is so seductive — and possibly misleading

How our health systems are working to prevent hospital drug shortages

Why health companies are branding themselves as tech companies